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Candida species cause cutaneous and systemic infections with a high mortality rate, especially 
in immunocompromised patients. The emergence of resistance to the most common antifungal 
drugs, also due to biofilm formation, requires the development of alternative antifungal agents. 
The antimicrobial peptide VLL-28, isolated from an archaeal transcription factor, shows comparable 
antifungal activity against 10 clinical isolates of Candida spp. Using a fluoresceinated derivative of this 
peptide, we found that VLL-28 binds to the surface of planktonic cells. This observation suggested 
that it could exert its antifungal activity by damaging the cell wall. In addition, analyses performed on 
biofilms via confocal microscopy revealed that VLL-28 is differentially active on all the strains tested, 
with C. albicans and C. parapsilosis being the most sensitive ones. Notably, VLL-28 is the first example 
of an archaeal antimicrobial peptide that is active towards Candida spp. Thus, this points to archaeal 
microorganisms as a possible reservoir of novel antifungal agents.
Candida species are the most prevalent opportunistic fungal pathogens worldwide. Candida spp. commonly dwell 
as commensal microbes colonizing the skin, oral cavities, and gastrointestinal and genital-urinary tracts of most 
healthy humans. When alterations in the host microbiota or in the host immune and defence system occur, 
Candida spp. can become pathogenic, causing numerous disorders ranging from cutaneous infections to severe 
systemic infections with a high mortality rate in hospitalized patients1–5.
Candida bloodstream infection is often associated with the presence of implanted medical devices, such as 
shunts, stents, prostheses, endotracheal tubes, and various types of catheters6–8, on which Candida species grow 
as a resilient biofilm capable of withstanding high antifungal concentrations. As expected, in patients with can-
didemia, biofilm-producing strains have been associated with increased morbidity and mortality compared to 
non-biofilm-producing ones9. Among Candida isolates, C. albicans represents the predominant specie, although, 
in recent years, an increasing incidence of fungal infections by non-albicans Candida species has been observed 
in hospital environments4,10–12. C. krusei, C. tropicalis, C. parapsilosis, C. glabrata have all been implicated in 
biofilm-associated infections13,14.
Biofilms are highly structured communities of enclosed microorganisms within a self-produced protective 
extracellular matrix, with biofilm-embedded cells showing properties that are distinct from planktonic cells15–17. 
In particular, the biofilm matrix acts as a protective barrier, making the microbial cells more resistant towards 
conventional antifungal therapeutics and the host immune system, as well as other environmental perturbations. 
Therefore, biofilm-forming Candida infections are difficult to treat, and biofilm-related (sessile) minimal inhib-
itory concentrations (MICs) are often extremely higher than the MICs for planktonic (non-biofilm) cells18,19. 
Furthermore, the variation of biofilm formation among Candida strains and/or the differential biofilm response 
to several antifungal classes contributes to the virulence traits. In addition to the presence of a secreted extracellu-
lar matrix, the enhanced drug resistance shown by biofilm-embedded cells is also related to (i) the local increase 
in cell density, (ii) the upregulation of efflux pumps, (iii) the alteration of sterols in their membranes, and iv) the 
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activation of stress response mechanisms. This leads to the onset of persistent cells, which are a subset of metabol-
ically dormant yeasts cells within biofilms20–23.
Because of the recalcitrance of Candida biofilms to treatment with conventional drugs, high antifungal 
doses in systemic therapy are needed to eradicate the infections, along with the removal of the colonized 
medical devices in the case of implantations24–26. Only three classes of antifungal drugs are currently being 
used to treat invasive candidiasis: azoles (i.e., fluconazole), echinocandins (i.e., caspofungin) and polyenes 
(i.e., amphotericin B)27. In recent years, the antifungal resistance of Candida spp., especially of non-albicans 
species, has been observed. For example, C. krusei was found to have a reduced susceptibility to flucona-
zole, while C. glabrata was reported to be resistant to both azoles and echinocandins28. Since amphotericin 
B resistance in Candida species remains extremely rare, this drug is the treatment of choice in monotherapy 
for life-threatening systemic candidiasis. However, with the onset of antifungal resistant pathogens, there is 
an increasing need to design new antimycotics and/or discover alternative agents that improve the fungicidal 
activity of the current antifungals.
Antimicrobial peptides (AMPs) with their extraordinary properties, such as broad-spectrum activity, rapid 
action and unlikely development of resistance, have become promising molecules as new antibiotics29,30. An 
example of such molecules is represented by cationic antimicrobial peptides (CAMPs), i.e., short and positively 
charged peptides with an amphipathic structure. CAMPs are active against Gram-positive and Gram-negative 
bacteria, as well as fungi and protozoa29–31. Regardless of their specific mechanism of action, the interaction 
of CAMPs with the bacterial cell membrane is the key step, which eventually leads either to the disruption of 
the membrane integrity or to the alteration of its electrochemical potential31,32. Interestingly, some CAMPs also 
exhibit toxicity towards eukaryotes, such as fungi, despite the different lipidic membrane compositions and the 
distinct structures of the cell wall33.
While the effect of some AMPs on biofilm formation, as well as their antimicrobial activity on 
biofilm-embedded cells, has already been investigated34–36, only a limited number of studies describes the effect 
of CAMPs on biofilm formation by fungal pathogens such as Candida37,38. Recently, we identified a cryptic 
CAMP-like peptide (designated as VLL-28) in the sequence of the archaeal transcription factor Stf7639, which 
is encoded by the hybrid plasmid–virus pSSVx infecting Sulfolobus islandicus40–42. The peptide was identified 
using an in silico tool developed to search for cryptic antimicrobial peptide-like sequences hidden in the primary 
structure of proteins32,43–46. VLL-28 displays chemical, physical and functional properties typical of CAMPs and 
acquires a defined structure in the presence of membrane mimetics47,48. Notably, this CAMP turned out to be 
toxic not only to Gram-negative and Gram-positive bacteria but also to C. albicans47. Therefore, in this study, 
we investigated the antifungal activity of VLL-28 towards pathogenic C. albicans and non-albicans Candida spp. 
isolated from blood infections. In particular, we show the in vitro ability of VLL-28 to (1) inhibit yeast cells growth 
in a planktonic state, (2) prevent cell adhesion, and (3) eradicate established biofilms.
Results
Antifungal activity of VLL-28 towards Candida spp. planktonic cells. MIC values for amphotericin 
B, anidulafungin, micafungin, caspofungin, 5-fluorocytosine, posaconazole, voriconazole, itraconazole, and 
fluconazole of 10 clinical isolates of Candida spp., as well as the reference strain C. albicans ATCC10231, are 
reported in Table S1. The antifungal activity of VLL-28, expressed as MIC and MFC values against the same panel 
of isolates, is shown in Table 1. Among them, the planktonic cells of C. tropicalis were the most susceptible to the 
peptide VLL-28 (MIC = 12.5 µM), followed by C. albicans, C. parapsilosis and C. krusei (MIC = 25 µM), while C. 
glabrata planktonic cells were the least sensitive, showing the highest MIC value of 50 µM. In addition, the activity 
of VLL-28 was also investigated in terms of minimum fungicidal concentration (MFC). The values were two-fold 
higher than the MIC values for all Candida species, except C. albicans 80 and C. tropicalis isolates for which the 
MFC values were four-fold higher than the corresponding MICs (Table 1).
Yeasts
amphotericin B VLL-28
MIC μg/mL MFC μg/mL MIC μg/mL (μM) MFC μg/mL (μM)
C. albicans ATCC10231 0.25 1 88.5 (25) 177 (50)
C. albicans 80 0.5 2 88.5 (25) 354 (100)
C. albicans 81 0.25 2 88.5 (25) 177 (50)
C. parapsilosis 3 0.5 2 88.5 (25) 177 (50)
C. parapsilosis 10 0.5 2 88.5 (25) 177 (50)
C. tropicalis 54 0.5 4 44.25 (12.5) 177 (50)
C. tropicalis 2 0.5 4 44.25 (12.5) 177 (50)
C. glabrata 28 0.25 2 177 (50) 354 (100)
C. glabrata 34 0.25 1 177 (50) 354 (100)
C. krusei 1 0.5 2 88.5 (25) 177 (50)
C. krusei 14 1 2 88.5 (25) 177 (50)
Table 1. Minimal fungicidal concentration (MFC) and minimal inhibition concentration (MIC) of 
amphotericin B and VLL-28 against Candida species.
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In vitro biofilm formation assay. Candida species were tested for the ability to produce biofilm using the 
crystal violet staining method, and the results are shown in Fig. 1. All the tested isolates turned out to be biofilm 
producers. At 24 hours, C. glabrata 34, C. krusei 14 and 1 were weak producers, all C. albicans isolates and C. gla-
brata 28 were moderate producers, and all C. tropicalis and C. parapsilosis were strong producers. At 48 hours, all 
Candida species, with the exception of the C. krusei, were strong producers.
Cellular localization of VLL-28. A fluorescein-labelled derivative of VLL-28 (VLL-28*) was used to study 
the cellular localization of the peptide in C. albicans and C. tropicalis using confocal laser scanning microscope 
(CLSM)49. C. albicans and C. tropicalis were chosen because these two strains are among the most sensitive to 
VLL-28 activity. The effectiveness of VLL-28* was found to be similar to that of the not labelled peptide50. C. albi-
cans and C. tropicalis, pre-incubated with MitoTracker Orange, were treated with VLL-28* at the concentration 
of 12.5 μM and 25 μM, respectively, for 15 min and 2 h. Confocal images showed that, for both strains, the green 
signal (VLL-28*) was uniformly localized at the cellular surface of the treated cells after 15 min and did not over-
lap with the red (MitoTracker) signal (Fig. 2). This indicates that the peptide interacts with the fungal surfaces, 
probably binding to the negatively charged phospholipids, and that no internalization occurs.
Inhibition of biofilm formation by VLL-28. Cell adhesion either on the host cell tissues or on abiotic 
surfaces is the first step during Candida biofilm formation. Therefore, we investigated whether VLL-28 could 
prevent biofilm production by interfering with the cell viability at sub-MIC concentrations. The minimum biofilm 
inhibitory concentration (MBIC) was determined by quantifying the metabolic activity of the adherent cells using 
the XTT assay (Fig. 3). The percentage of biofilm viability was strongly reduced for C. tropicalis, C. albicans and 
C. parapsilosis strains, with MBIC values of 12.5 µM, and for C. glabrata strains, with MBIC values of 25 µM, while 
no inhibition of cell adhesion was observed for both C. krusei isolates (Fig. 3).
Activity against preformed biofilms of Candida species. Biofilm formation in Candida confers to 
the embedded cells an increased resistance towards antifungal agents. Therefore, we extended our investigation 
to the anti-biofilm activity of VLL-28 on preformed Candida biofilms. One-day-old biofilms were exposed to 
increasing doses of the peptide, and its antifungal activity was quantified using the XTT reduction assay. VLL-28 
effectively reduced the viability of the cells embedded in the mature biofilms, with MBEC50 and MBEC80 of 50 μM 
and 100 μM, respectively, for C. albicans isolates and the reference strain. In addition, VLL-28 killed 50% of the 
cells in the preformed biofilm (MBEC50) of C. glabrata and C. parapsilosis isolates at a concentration of 100 μM. 
On the other hand, VLL-28 was less effective against the mature biofilms of C. tropicalis and C. krusei isolates 
(Fig. 4, Table S3).
CLSM was used to investigate the effect of VLL-28 on Candida preformed biofilms. Biofilms were grown 
on Nunc® Lab-Tek® II chambered cover glasses and stained using the LIVE/DEAD FungaLight Yeast Viability 
Kit. As shown by the differential staining with SYTO9 (green fluorescence, live cells) and propidium iodide (red 
or yellow-red fluorescence, dead cells), VLL-28 caused the death of most of the cells embedded in the mature 
biofilms of C. albicans (Figs 5a,b and S1a,b) and decreased the cell viability in those of C. parapsilosis (Figs 5d,e 
and S1d,e) and C. glabrata (Fig. 6a,b and S2a,b). In the case of C. tropicalis biofilm, images showed a thickness 
reduction of approximately 30% and the appearance of regions with lower density (Figs 6c,d and S2c,d) com-
pared to the untreated control. However, viable cells were detectable, which suggests that the peptide could have 
a fungistatic effect on the preformed biofilm of C. tropicalis. Regarding C. krusei, VLL-28 administration did not 
cause any visible change in the thicknesses and viability of its mature biofilm, which is consistent with what was 
observed both by CLSM imaging and by the XTT reduction assay (Figs 6e,f and S2e,f).
Figure 1. In vitro biofilm production. Candida isolates were grown in 96-well microtitre plates and their biofilm 
was quantified through staining with crystal violet after 24 and 48 hours of cultivation. Each value is the average 
of three independent experiments in triplicate. Error bars are the standard deviations.
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To verify whether the different effects on Candida biofilms could be traced back to the different ability of 
VLL-28 to penetrate the biofilm matrix, C. albicans and C. parapsilosis biofilms were treated with VLL-28* and 
analysed using CLSM. As shown, the distribution of VLL-28* mirrors that of the dead cells (red spots), i.e., the 
propidium iodide stained areas (Figs 5c,f and S1c,f).
Figure 2. VLL-28 intracellular localization detected using confocal laser scanner microscopy. Candida cells 
were incubated in PBS at different times with a dose of the peptide corresponding to their MIC values. VLL-28 
conjugated with FITC is coloured in green, while mitotracker is in red. Images of C. albicans and C. tropicalis 
cells are shown at 15 min (a,c) and 2 hours (b,d) posttreatment.
Figure 3. Effect of different concentrations of VLL-28 on cell viability of Candida species. Cell viability within 
the biofilm was assessed by measuring the reduction of XTT. The results are reported as the percentage relative 
to the untreated control. Technical and biological triplicates were conducted for all experiments, and statistical 
significance was determined using one-way ANOVA and Dunn’s test. *P value between 0.01 and 0.001; **P 
value < 0.001.
www.nature.com/scientificreports/
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Discussion
The high risk of invasive fungal infections within the increasing population of immunocompromised patients, 
along with the emergence of resistance to the most common antifungal drugs in Candida spp., also due to biofilm 
phenotypes, requires the development of new antifungal agents. Antimicrobial peptides might represent a very 
promising alternative, not only to treat planktonic Candida but also for biofilm-embedded Candida cells51.
Most of the currently used antifungal agents show a specific mechanism of action. For instance, azoles act 
by interfering with the biosynthesis of membrane ergosterol52,53, while echinocandins block the synthesis of cell 
wall 1,3 beta-glucan, and polyenes bind ergosterol and disrupt membrane integrity53,54. In contrast, amphipathic 
AMPs exert their antimicrobial activity by binding the cellular membrane and then increasing its permeabil-
ity31,32. Unlike classic antifungal drugs, the peculiar mechanism of action of AMPs hinders the development of 
microbial resistance.
VLL-28 is a cryptic antimicrobial peptide derived from a transcriptional factor of Sulfolobus islandicus39. A 
previous study has shown the ability of VLL-28 to inhibit the growth of bacteria and fungi in planktonic form47. In 
this study, we investigated the antifungal and anti-biofilm activity of VLL-28 against clinical isolates of C. albicans 
and non-albicans species. VLL-28 exhibited fungicidal activity against almost all the planktonic Candida spp. 
tested, with MIC values in the range of 12.5–50 µM. These data are comparable to the MIC values reported for 
several other natural and artificial AMPs55–60, as reported in Table S2. VLL-28 displayed a reduced activity only 
towards C. glabrata, which showed the highest MIC and MFC values (Table 1). The poor susceptibility of C. gla-
brata to various CAMPs has already been reported61 and may reflect the unique and distinctive features of the cell 
wall of this pathogen62. Interestingly, VLL-28 also exhibited strong fungicidal activity towards the planktonic cells 
of C. krusei, which is regarded as a potentially multidrug-resistant (MDR) pathogen. This is a naturally resistant 
specie to fluconazole (FLC), which has shown an increased resistance to both flucytosine and amphotericin B63, 
as well as cross-resistance to azoles64. In addition, the clinical failure of caspofungin towards C. krusei infections 
has been reported in recent years65.
The results obtained with the fluorescein-labelled peptide indicate that VLL-28 interacts primarily with the 
fungal surfaces. In fact, no internalization was observed. This confirms that VLL-28 behaves as a typical CAMP 
by damaging the cell membrane and/or the cell wall, thus, greatly decreasing the likelihood of the appearance of 
strains resistance.
The ability of Candida spp. to adhere to epithelial or endothelial surfaces, as well as to implanted medical 
devices by forming resilient biofilms, is an important virulence trait that promotes the persistence of the infec-
tion. Compared with planktonic cells, Candida biofilms are characterized by increased resistance to conventional 
antifungal drugs, in particular to amphotericin B and fluconazole66–68. Several factors have been suggested to be 
involved in the resistance of biofilm to antimicrobial drugs, including the expression of conventional resistance 
genes, such as those coding for efflux pumps69. In addition, the production of an extracellular matrix, which is a 
specific mechanism of the biofilm growth mode, limits drug penetration or even binds the antifungal agent and 
prevents it from reaching its cellular target20,21,70. Thus, an extremely limited drug arsenal is available to treat 
biofilm-related Candida infections. VLL-28 effectively prevents biofilm formation by reducing the cells’ adhesion 
to the abiotic surfaces of all the strains tested (except for C. krusei) at a concentration of the peptide that is 50% 
of the MIC value. The ability of this peptide to prevent biofilm formation is particularly important for medical 
device implantations. In fact, the microbial colonization of indwelling medical implants with subsequent biofilm 
formation can lead to severe complications associated with increased morbidity and mortality, such as blood-
stream infections and systemic inflammation8.
Figure 4. Antifungal activity of VLL-28 on cells in preformed Candida biofilms. Mature biofilms were exposed 
to the peptide at concentrations ranging from 6.25 to 100 μM for 24 h. Each data point shows the XTT activity of 
the VVL-28-treated biofilm normalized to the control (untreated), which was considered to be 100%. Technical 
and biological triplicates were run for all experiments. Statistical significance was determined using one-way 
ANOVA and Dunn’s test (for P values see Table S3).
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Infection by non-albicans Candida species is currently a highly active research area, as these species are 
becoming increasingly prevalent69. Notably, VLL-28 reduces the metabolic activity, not only of mature biofilms 
formed by C. albicans (80%) but also of those formed by C. glabrata and C. parapsilosis (50%), at concentrations 
from 2- to 4-fold higher than those needed for the planktonic state. This result is not unexpected because even 
conventional antifungals that exhibit anti-biofilm activity have MBECs several-fold higher than the MICs for the 
same isolates71–73. Furthermore, our finding is similar to those reported for several other AMPs (Table S2).
CLSM images showed a diffuse cell permeabilization in 1-day-old biofilm of C. albicans and C. glabrata treated 
with sub-MBEC values of VLL-28, while the effect on the mature biofilm cells of C. parapsilosis was focal. The 
fluorescein-labelled peptide distribution appeared to overlap permeabilized cell zones. The diffuse or focal VLL-
28 toxicity may depend on the different distributions of the cells on the abiotic surfaces after 24 hours of biofilm 
formation. In addition, VLL-28 caused a significant decrease of the biofilm biomass of C. tropicalis, but no cell 
Figure 5. CLSM of VLL-28 on preformed biofilm of C. albicans (a–c) and C. parapsilosis (d–f). Panels a and 
d show untreated biofilms stained using the LIVE/DEAD FungaLight Yeast Viability Kit. Panels b and e show 
biofilms treated with VLL-28 (50 µM) and stained as in a and d. Panels c and f show biofilms treated with VLL-28*.
www.nature.com/scientificreports/
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killing was observed in this case. This result may be explained by the ability of VLL-28 to affect the matrix struc-
ture/stability by interacting with one or more components, thus inducing disaggregation of the biofilm without 
cell killing. It is worth noting that drug diffusion to the cell community within a given biofilm can be affected not 
only by the overall extent of the matrix itself but also by its chemical nature74. Indeed, Al-Fattani and Douglas74 
demonstrated that C. tropicalis strains could form a compact extracellular matrix containing hexosamine-rich 
polysaccharides, which is poorly penetrated by antifungal agents.
In conclusion, we showed the ability of VLL-28 to exert antifungal activity against planktonic cells and mature 
biofilm of clinical isolates of C. albicans and non-albicans species, including Candida krusei, which is intrinsically 
resistant to fluconazole75. These results appear relevant and deserve further study with the perspective of develop-
ing alternative and/or complementary antifungal therapies.
Figure 6. CLSM of VLL-28 on preformed biofilm of C. glabrata (a,b), C. tropicalis (c,d) and C. krusei (e,f). 
Panels a, c and e show untreated biofilms. Panels b, d and f show biofilms treated with VLL-28 (50 µM). All the 
biofilms were stained using the LIVE/DEAD FungaLight Yeast Viability Kit.
www.nature.com/scientificreports/
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Materials and Methods
Yeast strains and culture conditions. The Candida species evaluated in this study included the C. albi-
cans ATCC 10231 reference strain and eight clinical isolates (Table 1) belonging to a collection of fungal strains 
previously established at the Department of Molecular Medicine and Medical Biotechnology (University of 
Naples Federico II). Identification was performed by subcultures on chromogenic agar (Chromid agar) (Becton 
Dickinson) and by biochemical characterisation using the Vitek II system (Biomerieux) and was confirmed by 
MS MALDI-TOF (Bruker).
Susceptibility to amphotericin B, anidulafungin, micafungin, caspofungin, 5-fluorocytosine, posaconazole, 
voriconazole, itraconazole, and fluconazole was assessed using the Sensititre Yeast One colorimetric microdilu-
tion method (Thermofisher). All strains were stored as 15% (v/v) glycerol stocks at −80 °C. Prior to each exper-
iment, cells were subcultured from the stocks onto Sabouraud dextrose agar (SDA) (Becton Dickinson) at 37 °C 
for 48 h.
Peptides. The peptide VLL-28 (VLLVTLTRLHQRGVIYRKWRHFSGRKYR) and its fluoresceinated derived 
form (VLLVTLTRLHQRGVIYRKWRHFSGRKYRGK*) (VLL-28*), bearing the chromophore fluorescein cou-
pled to the last lysine residue, were synthetized and purified to 95% homogeneity by Inbios (Napoli, Italy), as 
confirmed by LC–MS analysis.
Determination of the minimum inhibitory concentration (MIC) and the minimum fungicidal 
concentration (MFC). The antifungal activity of VLL-28 was determined using a standardized broth 
microdilution method (Clinical and Laboratory Standards Institute (CLSI) document M27-A2)76. Briefly, for each 
Candida species, the cell suspension was adjusted to 3 × 103 CFU/mL using a morpholinepropanesulfonic acid 
(MOPS)-buffered RPMI 1640 medium (R6504 - Sigma) supplemented with 0.2% (w/v) glucose. One hundred 
microlitre aliquots of these cell suspensions were dispensed into 96-well microtitre plates. Peptide stock solution 
was serially diluted using the same RPMI 1640 medium and added to the wells at a final concentration ranging 
from 3 µM to 100 µM, and the plate was incubated for 48 hours at 37 °C. Absorbance at 595 nm was measured 
using a microplate reader (Biorad mod 680). Amphotericin B at concentrations ranging from 0.25 to 2 µg/mL was 
chosen as the positive control because all the strains were sensitive to this agent according to the Sensititre Yeast 
One test.
The MIC was defined as the lowest concentration of the peptide that resulted in 90% growth inhibition after 
48 h of incubation. The test was conducted at least three times using independent cell suspensions. The minimum 
fungicidal concentration (MFC) was determined by transferring 50 µl aliquots of each sample, previously treated 
with concentrations equal to or higher than the MIC, onto SDA plates and incubating the plates at 37 °C for 24 h. 
The lowest peptide concentraiton that yielded no fungal growth on agar plates was defined as the MFC.
In vitro biofilm formation assay. Biofilms of Candida spp. were formed in flat-bottomed 96-well 
microplates as described by Stepanovic with some modifications77. For each strain, a cell suspension in RPMI 
1640 medium supplemented with 2% (w/v) glucose was adjusted to 1 × 106–5 × 106 CFU/mL as determined by 
cell counts using a haemocytometer Neubauer improved chamber. Plate wells were inoculated with 200 µL of 
standardized yeast suspension in triplicate and incubated at 37 °C for 90 minutes to allow cell adhesion. A nega-
tive control was prepared by inoculating 200 µL of a yeast suspension inactivated by boiling. After the adhesion 
phase, non-adherent cells were removed by thoroughly washing the wells with 0.15 M sterile phosphate-buffered 
saline (PBS, pH 7.2). Each well was then filled with 200 µL of fresh RPMI 1640, and the plate was incubated at 
37 °C for 24 h to allow biofilm formation.
To assess biofilm formation, the culture broth was gently aspirated, and each well was washed twice with PBS 
and dried at 60 °C for 30 minutes. The biofilm was stained by incubation for 30 min with 50 µL of a 1% (w/v) crys-
tal violet solution. Any excess of crystal violet was removed by washing with PBS before adding 150 µL of absolute 
ethanol to release the dye from the biofilm. The absorbance was measured at 590 nm using a Biophotometer 
(Eppendorf) and was related to the amount of biofilm produced. We used the classification introduced by 
Stepanović et al.77 with some modifications. The isolates tested were classified into four categories: non-adherent 
(NA), weakly adherent (WA), moderately adherent (MA), or strongly adherent (SA).
2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide (XTT)-reduction 
assay. The (XTT)-reduction assay has been used as a routine tool for the quantitative measurement of bac-
terial and fungal metabolic activity, growth and response to antimicrobial treatments78–82. After peptide treat-
ment, the medium was aspirated from each well to remove floating cells, and the wells were thoroughly washed 
twice with PBS. The assay was conducted as described by Barra et al.80 with some modifications. Two hundred 
microlitres of XTT solution was added to each well, and the plate was incubated in the dark for 30 min at 37 °C. 
Changes in the absorbance of XTT were measured spectrophotometrically at 490 nm using a microtitre plate 
reader (Biorad). An XTT cell proliferation Kit II was purchased from Roche Diagnostics. Viability ratios were 
computed for each well with respect to their relative controls.
Confocal laser scanning microscopy. CLSM was used to illustrate the effect of peptide (50 µM) on the 
viability and architecture of mature (24 h) biofilms of Candida species. Biofilm-forming Candida cells were grown 
on Nunc® Lab-Tek® II chambered cover glasses (Sigma), and the antifungal biofilm susceptibility was assayed as 
described above.
Biofilms were stained with two nucleic acid dyes using the LIVE/DEAD FungaLight Yeast Viability Kit: SYTO 
9 and propidium iodide (PI) (Molecular Probes). SYTO 9 penetrates both viable and nonviable cells, while PI 
www.nature.com/scientificreports/
9SCIeNtIFIC REPORts |         (2018) 8:17570  | DOI:10.1038/s41598-018-35530-0
penetrates only cells with damaged membranes (i.e., nonviable cells) and quenches the fluorescence emitted by 
SYTO 9. Dead and viable cells emit yellow-red and green fluorescence, respectively. Images were captured using 
an LSM 710 inverted confocal laser-scanning microscope (Zeiss) and analysed using CLSM Z-Stack analysis: 
depth measurements were taken at regular intervals across the biofilm, and three-dimensional images of mature 
biofilms were captured.
Cellular localization studies of VLL-28. Confocal laser-scanning fluorescence microscopy was used to 
study the intracellular target of the peptides49. Double staining of the C. albicans and C. tropicalis strains with 
FITC-labelled peptides and MitoTracker Orange (chloromethyl-H2-tetramethyl rosamine, Molecular Probes), 
a permanent mitochondrion-selective dye, was achieved as follows: a Candida cell suspension (200 µL; 3.2 × 106 
cells/mL of PBS) was incubated with 150 nM MitoTracker Orange for 15 min at 37 °C. The cells were washed with 
200 µL of PBS and treated for 15 min and 2 h with 25 µM and 12.5 µM FITC-labelled peptides for C. albicans and 
C. tropicalis, respectively. The cells were collected using centrifugation (5 min at 10,000 × g), suspended in 20 µL 
of PBS and examined by confocal microscopy using an LSM 710 confocal laser-scanning microscope equipped 
with a 63X objective lens.
Adhesion inhibition assay. The adhesion of Candida spp. was assayed using flat-bottomed 96-well 
microplates. For each isolate, 100 µL of cell suspension in RPMI medium adjusted to 1 × 106 CFU/mL was incu-
bated with 100 µL of RPMI containing serially double-diluted peptide concentrations in order to obtain the final 
sub-MIC concentrations for each yeast, ranging from 1.5 µM to 25 µM. The plate was then incubated at 37 °C with 
a shaking rate of 100 rpm; the positive control consisted of peptide-free wells. After a 60 min adhesion phase, the 
medium with unbound peptide was aspirated; non-adherent cells were removed by washing the wells with PBS, 
and 200 µL of fresh RPMI was added. The plate was incubated further at 37 °C for 24 h, and an XTT reduction 
assay was performed as described below.
The adhesion inhibitory activity of the peptide is referred to as the minimum biofilm inhibitory concentration 
(MBIC), which is defined as the minimum peptide concentration leading to an 80% reduction of biofilm forma-
tion compared to a peptide-free control sample.
Antifungal susceptibility testing of 24 h-old Candida biofilms. Candida biofilms were produced as 
described above; upon mature biofilm formation, the medium was aspirated, and each well was washed twice gen-
tly with 200 µL of PBS to remove planktonic cells. Peptide aliquots (200 µL per well) ranging from 6.25 to 100 µM 
were added, and the plate was incubated for 24 h. Peptide-free wells were included as positive controls. The bio-
film formation at 24 h and 48 h was quantified using the XTT reduction assay described below. The anti-biofilm 
activity of the peptide is referred to as the minimum biofilm eradication concentration (MBEC), which is defined 
as the minimum peptide concentration resulting in 80% disruption of the biofilm compared to a peptide-free 
control culture.
Statistical analysis. All experiments were performed in triplicate with the average and standard devia-
tion calculated for all measurements. Statistical differences among the groups of data were analysed by one-way 
ANOVA using Prism (version 7.00 for Windows; GraphPad Software, San Diego, CA) and Dunn’s test. In all the 
comparisons, a P value of 0.05 or lower was considered significant.
Availability of Data and Materials
The datasets used and/or analysed during the current study are available from the corresponding authors on 
reasonable request.
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